Dr. Schneider is the Chief Operating Officer for Solid Biosciences, responsible for overseeing corporate and technical operations, quality, patient advocacy, communications, corporate strategy, and human resources.
Read More
Patricia (Trish) Hurter, Dr. Patricia Hurter is CEO of Lyndra Therapeutics. Prior to Lyndra, Dr. Hurter was Senior Vice President of Pharmaceutical and Preclinical Sciences at Vertex Pharmaceuticals, Inc.
Mrs. Ballinger is President and Chief Operations Officer of Lyndra Therapeutics. In her 25+ year career, she has contributed to the development and commercialization of more than 15 leading-edge patient therapies.
Read More
Shawn M. Leland is the Founder and Chief Executive Officer of Elevation Oncology overseeing all day-to-day operations. Shawn brings over a decade of experience in medical affairs and business development for the pharmaceutical/biotech industry, with a focus on building collaborations to realize the full potential of targeted and personalized therapeutics.
Read More
Paul joined Flagship Pioneering in 2019 as Executive Partner, Flagship Pioneering and President, Pioneering Medicines. In his role at Flagship, Paul works with growth company CEOs and their teams to achieve the best attainable value for each company and serves on the boards of selected Flagship companies including Seres Therapeutics, Valo Health. As a member of Flagship’s senior leadership team, Paul is involved in strategic and operational aspects of Flagship, including leading Pioneering Medicines.
Read More
Thank you for your support for Season 2! We reflect and look forward to Season 3 on this episode!
Read More
As Chief Medical Officer Dr. Ticho is responsible for Stoke’s efforts to develop first-in-class RNA based disease-modifying medicines to treat severe genetic diseases. He is also co-founder and former CEO of Verve Therapeutics which is developing therapies to edit the genome and confer protection from cardiovascular disease.
Read More
Gregory J. Divis serves as Avadel’s Chief Executive Officer and a member of Avadel’s Board of Directors. Greg was appointed CEO in June of 2019, after previously serving in several leadership roles within the company, including Chief Operating Officer, Executive Vice President, and Chief Commercial Officer.
Read More
Chip has served as Genocea's President and Chief Executive Officer since February 2011 after serving as Chief Business Officer from August 2010 to February 2011. Chip has also served on Genocea's board of directors since February 2011.
Read More
Srini Ramanathan, Ph.D., joined Horizon Therapeutics in 2018. He leads Horizon’s research and development sciences, with portfolio oversight of discovery, preclinical research and development functions; he also oversees scientific due diligence for business development evaluations.
Read More
Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicine with over 15 years of experience in oncology drug discovery in both small biotechnology companies and large pharmaceutical companies.
Read MoreDr. Ethan Perlstein is the founder and CEO of Perlara PBC, the first biotech public benefit company established in 2014 that partners with highly motivated and entrepreneurial families and foundations to develop treatments and cures for genetic diseases.
Read More
Michel Detheux is the co-founder, President, and CEO of iTeos Therapeutics, and has held the role of CEO since the company’s inception in 2012. He previously served as a director at Ludwig Cancer Research from December 2010 to March 2012.
Read More